Catalyst
Slingshot members are tracking this event:
Amgen (AMGN) set for FDA action date for migraine treatment Erenumab on May 17th, 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 18, 2018
Occurred Source:
https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Migraine, Erenumab
